Your browser is no longer supported. Please, upgrade your browser.
Verve Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.38 Insider Own13.30% Shs Outstand47.99M Perf Week-3.65%
Market Cap1.59B Forward P/E- EPS next Y-2.52 Insider Trans0.13% Shs Float44.47M Perf Month-41.74%
Income-112.50M PEG- EPS next Q-0.48 Inst Own57.60% Short Float8.64% Perf Quarter-55.26%
Sales- P/S- EPS this Y-136.80% Inst Trans3.55% Short Ratio9.90 Perf Half Y-
Book/sh8.02 P/B3.98 EPS next Y64.20% ROA- Target Price66.75 Perf Year-
Cash/sh7.83 P/C4.08 EPS next 5Y- ROE- 52W Range29.50 - 78.00 Perf YTD0.06%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-60.37% Beta-
Dividend %- Quick Ratio19.50 Sales past 5Y- Gross Margin- 52W Low4.78% ATR3.38
Employees70 Current Ratio19.50 Sales Q/Q- Oper. Margin- RSI (14)23.39 Volatility9.40% 8.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-143.10% Profit Margin- Rel Volume0.90 Prev Close31.94
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume388.35K Price30.91
Recom1.50 SMA20-25.05% SMA50-30.94% SMA200-40.46% Volume144,826 Change-3.22%
Sep-24-21Initiated Stifel Hold $58
Jul-12-21Initiated William Blair Outperform $92
Jul-12-21Initiated JP Morgan Neutral $50
Jul-12-21Initiated Jefferies Buy $72
Jul-12-21Initiated Guggenheim Buy $84
Nov-29-21 08:00AM  
Nov-12-21 04:19AM  
Nov-10-21 06:30AM  
Nov-09-21 06:30AM  
Nov-08-21 06:04PM  
Nov-05-21 08:36PM  
Oct-28-21 08:49PM  
Oct-21-21 06:30AM  
Oct-17-21 09:01AM  
Oct-08-21 06:39AM  
Sep-27-21 06:30AM  
Sep-23-21 11:03AM  
Sep-15-21 11:14AM  
Aug-12-21 06:30AM  
Jun-28-21 01:17PM  
Jun-16-21 09:24PM  
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashe Andrew D.See RemarksDec 02Buy32.104,000128,420170,722Dec 06 08:12 AM
ADELMAN BURT ADirectorDec 02Buy31.344,700147,3044,700Dec 06 08:11 AM